Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.54 |
| ▸ | NAMPT | P43490 | 17/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21644282 | 1.00 | GPR119 (0.54) | GPR119NAMPTCYP2C9NR1H2 | |
| SCHEMBL8044737 | 1.00 | GPR119 (0.54) | GPR119NAMPTCYP2C9NR1H2 | |
| SCHEMBL29492542 | 0.91 | GPR119 (0.47) | GPR119NAMPTCYP2C9NR1H2 | |
| SCHEMBL15203186 | 0.88 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL30451669 | 0.88 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL14316367 | 0.88 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL20077751 | 0.88 | GPR119 (0.57) | GPR119NAMPTCYP2C9 | |
| SCHEMBL15229209 | 0.87 | NAMPT (0.53) | GPR119NAMPTCYP2C9 | |
| SCHEMBL14316365 | 0.87 | GPR119 (0.53) | GPR119NAMPTCYP2C9 | |
| SCHEMBL18298007 | 0.87 | NAMPT (0.53) | GPR119NAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2020223136-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331022-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA2 | GPR119 113/4885NAMPT 1156/4885CYP2C9 3369/4885 |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | GPR119 16/4885NAMPT 2006/4885CYP2C9 265/4885 |
| US-20220119351-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA2 | GPR119 156/4885NAMPT 937/4885CYP2C9 2677/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | GPR119 16/4885NAMPT 2006/4885CYP2C9 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.